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Results: No statistically significant changes to the PTV dose was noted 
during treatment (p= 0.8). Dose to the parotid glands (left and right 
respectively) changed significantly between the 1st and 30th fractions 
(p=0.02 and 0.01 respectively). Percentage weight loss between RT 
was significant (P=0.01) between the 1st and 30th fraction, as was the 
difference in the TS (p=0.02). There was no statistically significant 
difference in MUAC and MAMC. A negative correlation was found 
between the changes in weight (3.5%) between pre to mid treatment, 
with that of increased parotid gland dose. This leads us to hypothesize 
that a weight loss above 3.5% in the first half of treatment could 
potentially alert clinicians of likely dose increase in the parotid 
glands, necessitating adaptive planning strategies. 
Conclusions: There is a significant increase in dose to the parotid 
glands during treatment although the dose to the PTV remains 
relatively stable. Weight loss and Triceps thickness changes were the 
two most significant clinical parameters that changed during 
radiation. A negative correlation existed between early changes of 
these clinical factors and overall parotid dose changes during 
radiotherapy. A prospective study with more patients could now be 
designed to ascertain if a threshold percentage difference in Weight 
loss and TS changes could predict a significant parotid dose change.  
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Purpose/Objective: Numerous clinical trials have demonstrated that 
the loco-regional control and disease specific survival in patients with 
HNSCC can be significantly improved by reducing the total treatment 
time by the so called 'accelerated fractionation'. Such principle has 
most recently been demonstrated and confirmed in a large 
international randomized trial conducted by the IAEA as well as by a 
recent meta-analysis. The problems of overcoming hypoxia in head 
and neck cancers have been addressed in numerous clinical trials 
using different kinds of hypoxic modification and both the experience 
from major individual controlled clinical trials as well as a meta-
analysis has shown that such modification of hypoxia results in 
significantly better local control, disease-specific and overall survival. 
Repopulation and hypoxia are independent factors, and it is thus to be 
expected that the optimal treatment option is a reduced treatment 
time using concomitant hypoxic modification. Such treatment 
principle is also applied by some institutions and collaborative groups 
(such as DAHANCA), but the true value of adding a hypoxic modifier to 
a treatment schedule with accelerated fractionation has not been 
evaluated in a controlled clinical trial. 
Materials and Methods: A stratified, randomized phase III study of 
patients with HNSCC randomizes to accelerated radiotherapy ± 
Nimorazole. Radiotherapy will be given for both arms in 6 
fractions/week for a total dose 66-70Gy in 33-35 fractions & 
Nimorazole is to be administered in doses of approximately 1.2 g/m2 
body surface, 90 minutes prior to the first daily fraction. Quality 
assurance procedures are applied to ensure consistency and validity of 
the data. Biological materials are collected from the participating 
centers for analysis for hypoxia gene expression, as well as HPV/p16 
expression. 
Results: Patient recruitment started by the first of March 2012. 6 
centers out of 9 centers started patient’s recruitment. 47 patients are 
recruited to the trial by the beginning of December 2012. Collection 
of patient data is done through online electronic forms. Each center is 
asked to submit the radiotherapy treatment documentations of the 
first 5 recruited patients. Centers that use IMRT/3DCRT planning 
techniques are asked to upload the electronic plans of the first 5 
recruited patients on a specific FTP site. All plans are reviewed 
centrally in the trial central department by the quality assurance 
coordinator. Electronic plans could be viewed using virtual planning 
software. 
Conclusions: The trial is feasible to conduct in the participating 
centers. And treatment will be given with good quality standards. 
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Purpose/Objective: Human Papilloma Virus (HPV) status has evolved 
as one of the most important prognostic factors in head and neck 
cancer. We analyzed the relative impact of HPV-status and advanced 
radiotherapy (RT) techniques on outcome.  
Materials and Methods: Between Oct 2005 and Dec 2008 74 pts 
received definitive RT for oropharingeal cancer. In 62 pts we could 
retrospectively analyze HPV status by p16 immunohistochemistry and 
molecular analysis for HPV. P16 immunohistochemistry staining was 
performed using the CINtec® Histology V-Kit for qualitative detection 
of p16 antigen on tissue section. Both nuclear and/or cytoplasmic p16-
staining were considered to be positive. For HPV molecular biology, 
DNA extraction was performed using a Qiagen Kit. Molecular analysis 
was performed by nested PCR (AB-Analitica Kit). Mean age was 63 
years (35-84) and 84,7% of pts were male. Thirty-five pts (56.5%) 
presented with stage IV disease (all M0); 17 pts (27.4%) had base of 
tongue cancer and 34 pts (54.8%) had tonsillar cancer. In 33 pts 
(53,2%) RT was associated with concomitant chemotherapy with cis-
platinum. Seventeen pts (27.4%) underwent 3D simplified RT (3D-S, 
three field treatment with a single isocenter), followed by a 
photon/electron beam junction treatment and a 3D-conformal boost 
with a dose of 50 Gy to elective lymph node areas (CTV1) and 70 Gy to 
primary tumor and positive lymph nodes (CTV2). Twenty-two pts 
(35.5%) received 3D advanced RT (3D-A, 5 or 7 field conformal 
therapy) with doses of 50 Gy to CTV1 and 70 Gy to CTV2. Twenty-
three pts (37.1%) underwent intensity modulated RT (IMRT) with 
simultaneous integrated boost (SIB) with 2 dose levels (54-66 Gy in 30 
fractions) or 3 dose levels (54-60-69 Gy in 30 fractions). 
Results: Twenty-six pts. were P16+ (43,3%), 27 pts were PCR+ (45%) 
for HPV 16 and only one for HPV 18. Only 59 pts could be evaluated 
(two patients were lost to follow up at the time of analysis). Mean 
over all follow up is 39 months (3-80). OS, DFS and loco-regional 
control (LRC) at 3 and 5 years were 57,1,%, 51,9% and 79,6% and 
50,8%, 45,4%, 77,2% respectively. Univariate analysis based on the 
Kaplan-Meyer method (SPSS software) resulted in the identification of 
the following prognostic factors:  
Significant prognostic factor 
for OS 
p Significant prognostic factor 
for DFS 
p 
Smoking (cut-off > 10 pack 
years) 
,006 Smoking (cut-off > 10 pack 
years) 
,02 
Performance status (IK cut-
off 80) 
,000 Performance status (IK cut-off 
80) 
,000 
p16-positivity  ,000 p16-positivity  ,001 
PCR-positivity for HPV  ,007 PCR-positivity for HPV  ,03 
Treatment technique ,000 Treatment technique ,02 
 
LRC of P16+ pts was not influenced by treatment technique while in 
the HPV- cohort the 3 years DFS of pts treated with 3D-S, 3D-A and 
IMRT were 45,5%, 75% and 78% respectively, though these differences 
did not reach statistical significance for the relatively small number of 
patients. 
Conclusions: New techniques seem to be more relevant in outcome of 
p16 negative pts than in p16 positive pts probably because they allow 
a better high dose coverage of the target which may be more relevant 
in these prognostically less favourable patients. Further studies must 
be performed to confirm this hypothesis.  
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Purpose/Objective: There are a few reports of the radiotherapy for 
synchronous carcinomas in the head and neck (H&N) and esophagus. 
Purpose of this retrospective study is to analyze the results of 
definitive radiotherapy and find the possible prognostic factors. 
Materials and Methods: We reviewed the records of 48 patients with 
synchronous carcinoma in H&N and esophagus who were treated by 
definitive radiotherapy between 2000 and 2012 in our institution. The 
patients with distant metastasis were excluded in this study. 
Regarding head and neck carcinoma, the primary site was 
hypopharynx in 35 patients, larynx in 7, oropharynx in 3 and multiple 
primary sites in 3. Lymph node involvement was seen in 10 patients. 
Eighteen patients were classified to Stage I, 16 to Stage II, 6 to Stage 
III and 8 to Stage IV. Radiation dose in H&N ranged from 34Gy/17fr to 
70Gy/35fr with mean dose of 60Gy/30fr. Concerning esophageal 
carcinoma, single site in esophagus was involved in 23 patients and 
multiple sites in 25 patients. Lymph node metastasis was seen in 21 
patients. Twenty-four patients were classified to Stage I, 9 to Stage II, 
14 to Stage III and 1 to Stage IV. Radiation dose in esophagus ranged 
from 34Gy/17fr to 66Gy/33fr with mean dose of 60Gy/30fr. 
Concurrent 5-FU and cisplatin was administered to 41 patients, and 
the remaining 7 patients were treated by radiation alone. 
Results: The 3-year overall, and cause-specific survival rates were 
38.5% and 52.7% respectively. Advanced esophageal carcinoma stage 
(stage III or IV) had worse 3-year cause-specific survival rate than 
stage I or II esophageal carcinoma (63.8% vs. 24.4%, p=0.02).  
Concerning adverse events, 22 patients (45.8%) needed dmission 
management due to severe acute toxicity. Concurrent chemoradiation 
group had higher rate of admission than radiation alone group (51.2% 
vs. 14.3%). Eighteen patients (37.5%) experienced grade 3 or more 
chronic toxicity (CTCAE ver4.0). Five patients (10.4%) died from 
treatment related complications. 
Conclusions: Definitive concurrent chemoradiotherapy for 
synchronous carcinoma in H&N and esophagus may be a treatment 
option but intensity was so strong that the indication for large field 
radiotherapy and concurrent use of chemotherapy must be very 
cautiously considered. Advanced stage of esophageal carcinoma was 
worse prognostic factor for cause-specific survival rate. 
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Purpose/Objective: To evaluate the dose to carotid artery in patients 
treated with intensity modulated radiation therapy (IMRT) for 
oropharyngeal cancer.  
Materials and Methods: Ten patients with locally or regionally 
advanced oropharyngeal cancer were treated with IMRT. The primary 
tumour involvement was as follows: base of tongue (n=4), tonsil 
(n=2),vallecula (n=3), and soft palate (n=1). The TNM classification of 
the tumour was as follows: T2 (n=1), T3 (n=8), T4a (n=1), N0 (n=5), N1 
(n=2), N2b (n=1), N2c(n=2), and M0 (n=10). The planning CECT scan 
was obtained at 3 mm slice thickness. The right and left common, 
internal, and external carotid arteries were contoured from the level 
of sterno-clavicular joint to the base of skull. The following dose 
schedule was prescribed for IMRT: 70 Gy in 35 fractions (2 Gy per 
fraction) to GTV with 0.5-1.0 cm margin (CTV1), 63 Gy in 35 fractions 
(1.8 Gy per fraction) to high-risk CTV2, and 56 Gy in 35 fractions (1.6 
Gy per fraction) to the low-risk CTV3. A PTV margin of 5 mm was 
given to the respective CTV. The plan was normalized such that at 
least 95% of the volume of PTV1 to be covered by the 70 Gy isodose; 
no more than 20% of PTV1 to receive ≥77 Gy; and no more than 5% of 
PTV1 to receive ≥80.5 Gy. In addition, no more than 1% of any distinct 
PTV to receive ≤ 93% of the prescribed dose and no more than 1% of 
the tissue outside the PTV to receive ≥110% of the dose prescribed to 
PTV1. The treatment was delivered using 6 MV X-rays. Dose-volume 
histogram (DVH) was obtained for each of the 20 carotid arteries. 
Results: The median volume of the carotid artery was 6.2 cc (range, 
4.5-8.7 cc). The median of the mean dose to carotid artery was 58.4 
Gy (range, 53.3-64.3 Gy). The median of the maximum dose to carotid 
artery was 75.9 Gy (range, 61-79.1 Gy). The median and range of V40, 
V50, V60, and V70 were 5.7 cc (4.2-7.9 cc), 5.5 cc (4.1-7.8 cc), 3.8 cc 
(0.9-5.5 cc), and 1.2 cc (0.0-3.0 cc), respectively. With regard to the 
N0 cases, the median of mean and maximum dose to carotid artery 
was 58 Gy and 73.2 Gy respectively. The median of mean and 
maximum dose in N+ cases was 59.9 Gy and 77.3 Gy respectively.  
Conclusions: The dose heterogeneity in IMRT may contribute to 
increase in maximum dose to the carotid arteries. Long term clinical 
outcome may elucidate the risk of cerebrovascular events in patients 
treated with IMRT for oropharyngeal cancer.  
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Purpose/Objective: To compare the differences in resource utilisation 
between Cetuximab plus RT (EBRT) versus Cisplatin plus radiotherapy 
(CRT) taking in to account drug costs, clinical management and the 
costs of managing treatment related toxicity. Effects of treatment on 
quality of life, overall survival and local recurrence were also 
measured .  
Materials and Methods: 20 patients with stage 3 or 4 HNSCC were 
randomised between concomitant weekly Cetuximab or weekly 
Cisplatin plus XRT 70Gy in 35 fractions (10 Cetuximab, 10 Cisplatin). 
All drugs and hospital contacts were recorded to allow assessment of 
the health-economic impact of the management of toxicity additional 
to the initial cost of treatment. Data was collected for the acute 
phase, start of treatment to 6 weeks after completion of radiotherapy 
and late phase, from 6 weeks following completion of treatment to 6 
months following completion of treatment. Quality of life 
questionnaires were completed at baseline, at end of radiotherapy , 6 
weeks following completion of therapy and 6 months following 
completion of treatment. All patients have been followed up for 
greater than 24 months for survival and local recurrence rates. 
Biopsies have been retrospectively tested for p16 positivity by 
immunohistochemisty 
Results: Patients receiving Cisplatin required more intense 
management during the treatment and acute phase they were more 
likely to require overnight admission and required more laboratory 
and radiological investigation compared to those treatment with 
Cetuximab. Patients treated with Cisplatin also had more unplanned 
visits to hospital for management of the side effects of treatment. 
There was no significant difference between the two arm of the study 
for time spent with the head and neck CNS, Dietician or speech and 
language therapist. There were no differences in quality of life 
parameters between the 2 arms of the study although patients 
treatment with Cetuximab were significantly less likely to be using a 
feeding tube at 6 months. c2 p= 0.04. While the study was not 
powered to investigate differences in survival or local recurrence 
rates there was a statistically significant increase in local recurrence 
in patients treated by Cetuximab in this study. log rank p=0.014 
Conclusions: While the overall costs of drug treatment plus 
emergency admission are higher for Cetuximab when compared to 
Cisplatin terms patients undergoing Cisplatin and Radiotherapy 
require significantly more non routine intervention and care than 
patients receiving Cetuximab and Radiotherapy in this randomised 
study and this should be taken in to account when planned further 
trials. A study comparing cisplatin and Cetuximab to investigate 
quality of life and late functional effects of treatment could be viable 
within the NHS. Any future study should also be powered to 
investigate potential differences in overall survival and local 
recurrence rates 
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Purpose/Objective: To report our initial clinical experience of Helical 
Tomotherapy (HT) in the treatment of locally advanced oropharynx 
and inoperable oral cavity carcinoma, in terms of response, acute and 
late toxicity rates. 
Materials and Methods: Between February 2008 and January 2011, 24 
consecutive patients, 15 with oropharyngeal and 9 with oral squamous 
cell carcinoma were treated with exclusive radiotherapy or 
concomitant chemoradiotherapy. Simultaneous integrated boost (SIB) 
in 30 fractions scheme was prescribed to all patients, using Helical 
Tomotherapy. Patients treated with exclusive radiotherapy received a 
dose of 67.5 Gy in 2.25 Gy daily fractions for tumor and 63 Gy in 2.1 
